MedTrace Logo

Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination

NCT01586169 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2012-04-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether the triple co administration of albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that consists to treat with albendazole plus ivermectin together and a week later to treat with azithromycin in areas co endemic for lymphatic filariasis and trachoma.

Conditions

  • Parasitic Diseases
  • Bacterial Diseases

Interventions

DRUG

triple co administration at once of the combination of Albendazole + ivermectin + azithromycin

Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once

Sponsors & Collaborators

  • International Trachoma Initiative

    collaborator OTHER

  • Centre d'Appui à la lutte contre la Maladie

    lead OTHER

Principal Investigators

  • Samba O Sow, MD, MPH · CNAM, Mali

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Mali

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01586169 on ClinicalTrials.gov